Company: HCTI
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001213900-25-076686
Chunk: 107

Company: Healthcare Triangle, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 8
Chunk 107
---
 2024-01,
“Compensation—Stock Compensation (Topic 718): Scope Applications of Profits Interests and Similar Awards” (“ASU
2024-01”). ASU 2024-01 adds an example to Topic 718 which illustrates how to apply the scope guidance to determine whether profits
interests and similar awards should be accounted for as share-based payment arrangements under Topic 718 or under other U.S. GAAP. ASU
2024-01 is effective for annual periods beginning after December 15, 2025, although early adoption is permitted. Upon adoption, ASU 2024-01
is not expected to have an impact on the Company’s consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03,
“Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40).” This standard
requires disclosure of specific information about costs and expenses and becomes effective January 1, 2027. The Company is currently evaluating
the impact of this standard on our consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-04,
“Debt - Debt with Conversions and Other Options (Subtopic 470-20): Induced Conversions of Convertible Debt Instruments” (“ASU
2024-04”). ASU 2024-04 clarifies the requirements for determining whether certain settlements of convertible debt instruments, including
convertible debt instruments with cash conversion features or convertible debt instruments that are not currently convertible, should
be accounted for as an induced conversion. The requirements of ASU 2024-04 are effective for the Company for fiscal years beginning after
December 15, 2025, and interim periods within those periods. The Company is currently evaluating the impact of this standard on our consolidated
financial statements and related disclosures.

30

Item 2. Management’s discussion and analysis
of financial condition and results of operations. 

The following discussion summarizes the significant
factors affecting the operating results, financial condition, liquidity, and cash flows of our Company as of and for the periods presented
below. The following discussion and analysis should be read in conjunction with the condensed consolidated financial statements and the
related notes thereto, and the consolidated financial statements and the related notes thereto all included elsewhere in this prospectus.
The statements in this discussion regarding industry outlook, our expectations regarding our future performance, liquidity